Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina

ROPing AI into Care

Landmark paper: JM Brown et al., “Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks”, JAMA Ophthalmol, 136, 803-810 (2018). PMID: 29801159.

Retinopathy of prematurity (ROP), a retinal vasoproliferative disease affecting premature infants, is a leading cause of childhood blindness worldwide. Standard clinical criteria have been established for diagnosis and treatment, and severe ROP can be successfully treated – if it is diagnosed early. The Early Treatment for Retinopathy of Prematurity multicenter clinical trial showed that “plus disease” is the most important parameter for identifying severe treatment-requiring ROP. Plus disease is defined as arterial tortuosity and venous dilation in the posterior pole, and accurate and consistent diagnosis of plus disease is critical to ensure that infants at risk of blindness receive the appropriate treatment. An intermediate stage – the pre-plus category – is defined as retinal vascular abnormalities that are insufficient for plus disease, but have more arterial tortuosity and venous dilation than normal.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Kang Zhang

Zhang is Professor of Ophthalmology and Chief of Ophthalmic Genetics at the University of California San Diego, CA, USA. His clinical and research focuses are on novel disease gene targets and treatment, gene and stem cell-based therapies in AMD, diabetic retinopathy, and inherited retinal degeneration. His laboratory uses genetic analyses to gain insights into the molecular mechanisms that underpin macular degeneration and other eye diseases; this knowledge is then used to make genetic changes that either protect the retina from damage, or actively encourage regeneration. Zhang was voted to the 2018 Power List.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register